<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04922905</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/20/0178</org_study_id>
    <nct_id>NCT04922905</nct_id>
  </id_info>
  <brief_title>Nervous System Symptoms Associated With COVID 19</brief_title>
  <acronym>NS-COV</acronym>
  <official_title>Nervous System Symptoms Associated With COVID 19 : NS-COV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim to prospectively evaluate the neuropsychiatric symptoms of patients infected&#xD;
      with the SARS-CoV-2 virus by a standardized neuropsychiatric examination : the global CASE&#xD;
      scale (Clinical Assessment Scale in Autoimmune Encephalitis), and the prevalence of&#xD;
      disturbances of consciousness, focal neurological deficit, cognitive impairment, headache,&#xD;
      anosmia, sleep disturbances, impaired autonomic nervous system and peritraumatic stress.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2020</start_date>
  <completion_date type="Actual">April 2, 2021</completion_date>
  <primary_completion_date type="Actual">May 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an observational, prospective, cross-sectional and monocentric cohort study</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients in the Neuro + and Neuro- groups</measure>
    <time_frame>Baseline T0 : inclusion visit</time_frame>
    <description>The percentage is deducted from the score on a global scale by the Clinical Assessment Scale in Autoimmune Between 0 and 1, patients will be classified in the Neuro group, if this score is greater than or equal to 2, patients will be classified in the Neuro + group.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>NEURO +</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients &quot;neuro +&quot; are those with a CASE score â‰¥ 2, &quot;Neuro +&quot; patients will benefit from additional evaluations using paraclinical examinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NEURO -</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients &quot;neuro -&quot; are those with a CASE score &lt; 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NEURO +</intervention_name>
    <description>The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :&#xD;
The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)&#xD;
the Peri traumatic distress inventory (Jehel et al., 2005)&#xD;
and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)&#xD;
Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed.</description>
    <arm_group_label>NEURO +</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NEURO -</intervention_name>
    <description>The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :&#xD;
The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)&#xD;
the Peri traumatic distress inventory (Jehel et al., 2005)&#xD;
and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)</description>
    <arm_group_label>NEURO -</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Being hospitalized at the Toulouse University Hospital for a COVID-19 infection proven&#xD;
             by a probable PCR or COVID-type examination on the chest scan&#xD;
&#xD;
          -  Have given oral consent for the collection of clinical neurological data&#xD;
&#xD;
          -  Be in a clinical state compatible with a 30-minute neurological examination&#xD;
&#xD;
          -  Be French-speaking&#xD;
&#xD;
          -  Be affiliated to a Social Security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal of the neurological examination&#xD;
&#xD;
          -  History of neurological pathology at a severe stage&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Persons with tutors or curators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Rafiq, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nervous system</keyword>
  <keyword>coronavirus</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Nervous system symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

